CY1105364T1 - Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης - Google Patents

Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης

Info

Publication number
CY1105364T1
CY1105364T1 CY20061100716T CY061100716T CY1105364T1 CY 1105364 T1 CY1105364 T1 CY 1105364T1 CY 20061100716 T CY20061100716 T CY 20061100716T CY 061100716 T CY061100716 T CY 061100716T CY 1105364 T1 CY1105364 T1 CY 1105364T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
immune modulation
protein
disclosed
Prior art date
Application number
CY20061100716T
Other languages
English (en)
Inventor
Reginald M. Gorczynski
David A. Clark
Original Assignee
Trillium Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trillium Therapeutics Inc. filed Critical Trillium Therapeutics Inc.
Publication of CY1105364T1 publication Critical patent/CY1105364T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)

Abstract

Κοινοποιούνται μέθοδοι και συνθέσεις για την επαγωγή ανοσοποιητικής ανταπόκρισης. Οι μέθοδοι περιλαμβάνουν την χορήγηση μιας αποτελεσματικής ποσότητας από πρωτεΐνη ΟΧ-2 ή ενός νουκλεϊκού οξέως (nucleic acid) που κωδικοποιεί μία πρωτεΐνη ΟΧ-2. Οι μέθοδοι είναι χρήσιμες για την παρεμπόδιση της απόρριψης μοσχεύματος, της απώλειας εμβρύου, της ασθένειας της αυτό-ανοσοποίησης και των αλλεργιών. Κοινοποιούνται επίσης μέθοδοι και συνθέσεις για την παρεμπόδιση της καταστολής ανοσοποίησης. Οι μέθοδοι περιλαμβάνουν την χορήγηση μιας αποτελεσματικής ποσότητας ενός παράγοντα που εμποδίζει το ΟΧ-2.
CY20061100716T 1997-11-07 2006-06-05 Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης CY1105364T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07
PCT/CA1998/001038 WO1999024565A1 (en) 1997-11-07 1998-11-06 Methods and compositions for immunomodulation

Publications (1)

Publication Number Publication Date
CY1105364T1 true CY1105364T1 (el) 2010-03-03

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100716T CY1105364T1 (el) 1997-11-07 2006-06-05 Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης

Country Status (13)

Country Link
US (6) US6338851B1 (el)
EP (1) EP1032662B1 (el)
JP (2) JP4584447B2 (el)
AT (1) ATE319825T1 (el)
AU (1) AU748587B2 (el)
CA (1) CA2308765C (el)
CY (1) CY1105364T1 (el)
DE (1) DE69833779T2 (el)
DK (1) DK1032662T3 (el)
ES (1) ES2260852T3 (el)
HK (1) HK1030625A1 (el)
PT (1) PT1032662E (el)
WO (1) WO1999024565A1 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
ATE319825T1 (de) 1997-11-07 2006-03-15 Trillium Therapeutics Inc Verfahren und zusammensetzungen zur immunomodulation
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
CA2369454A1 (en) * 1999-04-13 2000-10-19 Schering Corporation Uses of mammalian ox2 protein and related reagents
AU6615500A (en) * 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
AU2001242159B2 (en) * 2000-03-17 2006-04-27 Trillium Therapeutics Inc. Methods and compositions for immunoregulation
WO2001080880A2 (de) * 2000-04-22 2001-11-01 Stefan Barth Apoptotika
WO2002011762A2 (en) * 2000-08-03 2002-02-14 Gorczynski Reginald M Methods and compositions for modulating tumor growth
AUPR069500A0 (en) 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
ATE406385T1 (de) * 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
EP1341902A2 (en) 2000-12-08 2003-09-10 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
JP2005511012A (ja) 2001-08-10 2005-04-28 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトｃＤＮＡおよびタンパク質およびその使用
EP1439857B1 (en) * 2001-10-12 2009-02-25 Schering Corporation USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
EP1585545A4 (en) * 2002-12-27 2006-04-12 Schering Corp PROCESS FOR INDUCING AND MAINTAINING IMMUNE COMPATIBILITY
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
WO2008085963A1 (en) * 2007-01-05 2008-07-17 University Of Florida Research Foundation, Inc. Materials and methods for the detection, prevention and treatment of autoimmune disease
EP2185593B1 (en) 2007-07-25 2017-12-13 Alexion Pharmaceuticals, Inc. Compositions for treating autoimmune disease
WO2009014745A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
ES2492498T3 (es) 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
CA2786692A1 (en) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
EP2534178A4 (en) 2010-02-11 2013-08-07 Alexion Pharma Inc THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
WO2012125182A1 (en) 2011-03-11 2012-09-20 Synageva Biopharma Corp Npp1 fusion proteins
US9535075B2 (en) 2010-03-25 2017-01-03 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
AU2015364411A1 (en) 2014-12-19 2017-06-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
CA3004048A1 (en) 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
CA3096821A1 (en) 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
WO2019084682A1 (en) 2017-10-30 2019-05-09 Mcmaster University Methods for the diagnosis and treatment of endometriosis
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
GB202303291D0 (en) * 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580812A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
WO1997021450A1 (en) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
ATE219376T1 (de) * 1996-03-20 2002-07-15 Bristol Myers Squibb Co Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
ATE319825T1 (de) * 1997-11-07 2006-03-15 Trillium Therapeutics Inc Verfahren und zusammensetzungen zur immunomodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
AU2001242159B2 (en) 2000-03-17 2006-04-27 Trillium Therapeutics Inc. Methods and compositions for immunoregulation
ATE406385T1 (de) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Verkürztes cd200
CA2448668A1 (en) 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
EP1032662A1 (en) 2000-09-06
US6749854B2 (en) 2004-06-15
CA2308765C (en) 2010-10-12
US7902151B2 (en) 2011-03-08
US6652858B2 (en) 2003-11-25
AU1017399A (en) 1999-05-31
ATE319825T1 (de) 2006-03-15
US20020086011A1 (en) 2002-07-04
DE69833779D1 (de) 2006-05-04
WO1999024565A1 (en) 1999-05-20
US6984625B2 (en) 2006-01-10
CA2308765A1 (en) 1999-05-20
EP1032662B1 (en) 2006-03-08
US20090232825A1 (en) 2009-09-17
JP2010155846A (ja) 2010-07-15
JP4584447B2 (ja) 2010-11-24
AU748587B2 (en) 2002-06-06
ES2260852T3 (es) 2006-11-01
US20020151485A1 (en) 2002-10-17
US6338851B1 (en) 2002-01-15
HK1030625A1 (en) 2001-05-11
US20020103151A1 (en) 2002-08-01
JP2001522867A (ja) 2001-11-20
US20110206668A1 (en) 2011-08-25
DK1032662T3 (da) 2006-07-03
PT1032662E (pt) 2006-07-31
DE69833779T2 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
CY1105364T1 (el) Μεθοδοι και συνθεσεις διαμορφωσης ανοσοποιησης
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
EP1009440A4 (en) METHODS OF INHIBITING RESPONSES ASSOCIATED WITH IMMUNOSTIMULATOR DNA
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
NO891818L (no) T4-reseptor-protein, relaterte dna-sekvenser samt fremstilling derav.
ES2153671T3 (es) Peptidos neuroactivos.
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
ATE141946T1 (de) Hiv-2-virusvarianten
NO885670D0 (no) Fortilsetning og for som inneholder denne tilsetning.
DE59710609D1 (de) Mittel zur Herstellung von Leder
DK317288D0 (da) Hybridprotein af humant protein c og dets fremstilling samt dna, som koder det
NO881658D0 (no) Bifunksjonelle proteiner.
ES2079481T3 (es) Un procedimiento para la determinacion de la actividad funcional de la proteina s o de la proteina c libre en una muestra de plasma.
NO873859D0 (no) Protein som har antikoagulerende og antimetastatiske egenskaper.
IT8621222A0 (it) Procedimento di (co)polimerizzazione di alfa-olefine in presenza di antiossidanti.
NO913035L (no) (2r)-2-(di(2-propyl)fosfonylmetoksy)-3-p-toluensulfonyloksy-1-trimetylacetoksypropan, fremgangsmaate for fremstilling og anvendelse derav.
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
DE3860646D1 (de) Thermoplastische siliconkautschukpfropfpolymerisate (i).
DE68910100D1 (de) Mittel zur Bluttrennung.
DE69015372D1 (de) Protein-testverfahren.
DE69011802D1 (de) Silikonelastomer-Emulsionen.
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
ES2012063B3 (es) Procedimiento mejorado para obtencion de p-cimeno y alquilbencenos homologos.
DK0588177T3 (da) Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet